0001140361-21-035296.txt : 20211025 0001140361-21-035296.hdr.sgml : 20211025 20211025163037 ACCESSION NUMBER: 0001140361-21-035296 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20211025 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211025 DATE AS OF CHANGE: 20211025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 211344479 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 brhc10030026_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2021

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey
  
07446
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ADMA
Nasdaq Global Market
Preferred Share Purchase Rights
 -
Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01
Other Events

On October 25, 2021, ADMA Biologics, Inc., a Delaware corporation (the “Company”), announced that it has completed the sale of 57.5 million shares of common stock, $0.0001 par value per share (the “Common Stock”), inclusive of 7.5 million shares of Common Stock issued and sold pursuant to the full exercise of the Underwriters’ (as defined below) option to purchase additional shares of Common Stock pursuant to Section 2 of the Underwriting Agreement, dated as of October 21, 2021, entered into by and between the Company and Raymond James & Associates, Inc., as representative of the several underwriters named therein (the “Underwriters”). The Company received gross proceeds of $57.5 million before deducting the underwriting discounts and commissions and fees and expenses payable by the Company in connection with offering. Raymond James & Associates, Inc. and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01
Exhibits

(d) Exhibits

Exhibit No.
Description
Opinion of Morgan, Lewis & Bockius LLP
Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)
Press Release of the Company, dated October 25, 2021
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 25, 2021
ADMA Biologics, Inc.
   
 
By:
/s/ Brian Lenz
   
Name:
Brian Lenz
   
Title:
Executive Vice President and Chief Financial Officer


EX-5.1 2 brhc10030026_ex5-1.htm EXHIBIT 5.1
Exhibit 5.1

 
October 25, 2021
ADMA Biologics, Inc.
465 State Route 17
Ramsey, NJ 07446
 
Re:
ADMA Biologics, Inc. Registration Statement on Form S-3 (333-256643)
 
Ladies and Gentlemen:
 
We have acted as counsel for ADMA Biologics, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale by the Company of 57,500,000 shares (the “Shares”) of common stock, $0.0001 par value per share, of the Company (the “Common Stock”) pursuant to that certain Underwriting Agreement, dated October 21, 2021, by and between the Company and Raymond James & Associates, Inc., as representative of the several underwriters named therein (the “Underwriting Agreement”).
 
As to all matters of fact (including factual conclusions and characterizations and descriptions of purpose, intention or other state of mind), we have relied, with your permission, entirely upon written actions by the Board of Directors of the Company and certificates of certain officers of the Company and have assumed, without independent inquiry, the accuracy of those certificates and written actions by the Board of Directors of the Company.
 
As counsel to the Company, in rendering the opinions hereinafter expressed, we have examined and relied upon originals or copies of such corporate records, agreements, documents and instruments as we have deemed necessary or advisable for purposes of this opinion, including (i) the certificate of incorporation and bylaws of the Company, each as amended to date, (ii) the Company’s registration statement on Form S-3 (Registration No. 333-256643) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), which was declared effective on August 3, 2021, (iii) the Prospectus Supplement, dated October 21, 2021, filed by the Company with the Commission on October 21, 2021 and the accompanying base prospectus, (iv) the Underwriting Agreement and (v) the written actions of the Board of Directors of the Company referenced above.
 
This opinion is limited solely to the Delaware General Corporation Law without regard to choice of law, to the extent that the same may apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of events occurring, circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed in this opinion.
 
 
Morgan, Lewis & Bockius llp
   
  502 Carnegie Center
  Princeton, NJ  08540-6241  +1.609.919.6600
  United States  +1.609.919.6701

ADMA Biologics, Inc.
October 25, 2021
Page 2
 
Based on such examination and subject to the foregoing, we are of the opinion that the Shares, when issued by the Company and delivered by the Company against payment therefor as contemplated by and in accordance with the procedures set forth in the Underwriting Agreement, will be validly issued, fully paid and non-assessable.
 
We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the Prospectus. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission thereunder. In rendering this opinion, we are opining only as to the specific legal issues expressly set forth herein, and no opinion shall be inferred as to any other matter or matters. This opinion is intended solely for use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose.
 
 
Very truly yours,
   
 
/s/ Morgan, Lewis & Bockius LLP


EX-99.1 3 brhc10030026_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
 
RAMSEY, NJ and BOCA RATON, FL, October 25, 2021 -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 7.5 million shares of common stock.  The gross proceeds from the exercise of the overallotment option were $7.5 million, bringing the total gross proceeds to ADMA from the offering to $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
 
ADMA intends to use the net proceeds from this offering (i) to advance the commercial sales of its U.S. Food and Drug Administration (FDA)-approved products through the procurement of raw materials for the manufacturing of BIVIGAM® and ASCENIV™; (ii) to expand its plasma collection facility network; (iii) to scale up the manufacturing capacity of its Boca Raton facility and to make continuous improvements in order to adhere to current Good Manufacturing Practice (cGMP) compliance; (iv) to explore business development opportunities; and (v) for general corporate purposes and other capital expenditures.
 
Raymond James & Associates, Inc. and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering.
 
The offering of the securities described above was made by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on August 3, 2021. The final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC on October 21, 2021 and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by e-mail at prospectus@cantor.com.
 
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
 
About ADMA Biologics, Inc. (ADMA)
 
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
 
Cautionary Note Regarding Forward-Looking Statements
 
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include statements about ADMA’s intended use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
 
COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com


 EX-101.SCH 4 adma-20211025.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 adma-20211025_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 adma-20211025_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Preferred Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 7 adma-20211025_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 image01.jpg begin 644 image01.jpg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end GRAPHIC 9 image02.jpg begin 644 image02.jpg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end GRAPHIC 10 image03.jpg begin 644 image03.jpg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end GRAPHIC 11 image04.jpg begin 644 image04.jpg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end XML 12 brhc10030026_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2021-10-25 2021-10-25 0001368514 us-gaap:CommonStockMember 2021-10-25 2021-10-25 0001368514 us-gaap:PreferredStockMember 2021-10-25 2021-10-25 false 0001368514 0 8-K 2021-10-25 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false Common Stock ADMA NASDAQ Preferred Share Purchase Rights NASDAQ false XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 25, 2021
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 25, 2021
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36728
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001368514
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Preferred Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Preferred Share Purchase Rights
Trading Symbol 0
Security Exchange Name NASDAQ
EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#65,<.&7J/P$ #P" / M " 980 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #'@UE3)!Z; MHJT #X 0 &@ @ $"$@ >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " #'@UE399!YDAD! #/ P $P M @ 'G$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" Q %% ! end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10030026_8k.htm adma-20211025.xsd adma-20211025_def.xml adma-20211025_lab.xml adma-20211025_pre.xml brhc10030026_ex5-1.htm brhc10030026_ex99-1.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true false JSON 20 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10030026_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "adma-20211025_def.xml" ] }, "inline": { "local": [ "brhc10030026_8k.htm" ] }, "labelLink": { "local": [ "adma-20211025_lab.xml" ] }, "presentationLink": { "local": [ "adma-20211025_pre.xml" ] }, "schema": { "local": [ "adma-20211025.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 2, "nsprefix": "adma", "nsuri": "http://admabiologics.com/20211025", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10030026_8k.htm", "contextRef": "c20211025to20211025", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10030026_8k.htm", "contextRef": "c20211025to20211025", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 21 0001140361-21-035296-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-035296-xbrl.zip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